294 related articles for article (PubMed ID: 25244582)
1. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?
Chaparro M; Gisbert JP
Expert Opin Drug Saf; 2014 Dec; 13(12):1749-62. PubMed ID: 25244582
[TBL] [Abstract][Full Text] [Related]
2. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.
Gisbert JP; Chaparro M
Am J Gastroenterol; 2013 Sep; 108(9):1426-38. PubMed ID: 23752881
[TBL] [Abstract][Full Text] [Related]
3. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
4. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
Khan N; Asim H; Lichtenstein GR
Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
[TBL] [Abstract][Full Text] [Related]
5. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
[TBL] [Abstract][Full Text] [Related]
7. [Biological therapy in women with inflammatory bowel disease during pregnancy].
Koželuhová J; Balihar K; Janská E; Fremundová L; Matějovič M
Vnitr Lek; 2014; 60(7-8):630-4. PubMed ID: 25130641
[TBL] [Abstract][Full Text] [Related]
8. [Anti-TNF therapy in inflammatory bowel diseases during pregnancy and breast-feeding].
Persić M
Acta Med Croatica; 2013 Apr; 67(2):157-64. PubMed ID: 24471298
[TBL] [Abstract][Full Text] [Related]
9. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
Roseira J; Ramos J
Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
11. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy.
Zelinkova Z; de Haar C; de Ridder L; Pierik MJ; Kuipers EJ; Peppelenbosch MP; van der Woude CJ
Aliment Pharmacol Ther; 2011 May; 33(9):1053-8. PubMed ID: 21366638
[TBL] [Abstract][Full Text] [Related]
12. "Paradoxical" arthralgia occurring under anti-TNFα treatment for inflammatory bowel disease.
Sondag M; Verhoeven F; Guillot X; Prati C; Briot C; Vuitton L; Koch S; Wendling D
Joint Bone Spine; 2018 Jan; 85(1):133-134. PubMed ID: 28115270
[No Abstract] [Full Text] [Related]
13. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
[TBL] [Abstract][Full Text] [Related]
15. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
Verma HD; Scherl EJ; Jacob VE; Bosworth BP
J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
[TBL] [Abstract][Full Text] [Related]
16. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
Ben-Horin S; Mazor Y; Yanai H; Ron Y; Kopylov U; Yavzori M; Picard O; Fudim E; Maor Y; Lahat A; Coscas D; Eliakim R; Dotan I; Chowers Y
Aliment Pharmacol Ther; 2012 Mar; 35(6):714-22. PubMed ID: 22288419
[TBL] [Abstract][Full Text] [Related]
17. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
18. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
19. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions.
Leung Y; Panaccione R; Ghosh S; Seow CH
Can J Gastroenterol Hepatol; 2014 Oct; 28(9):505-9. PubMed ID: 25101334
[TBL] [Abstract][Full Text] [Related]
20. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy.
Picardo S; Seow CH
Drugs; 2019 Jul; 79(10):1053-1063. PubMed ID: 31183768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
